European Commission Grants Conditional Marketing Authorization for Amgen's Lumykras, a KRAS G12C Inhibitor for Cancer
First KRAS G12C Targeted Therapy Enters the European Market
The European Commission (EC) has granted Conditional Marketing Authorization (CMA) for Lumykras (sotorasib), Amgen's KRAS G12C inhibitor. This approval is for adult patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have progressed after prior treatment. As the first KRAS-targeted cancer therapy in Europe, it has garnered significant attention. It is medically recognized as a breakthrough in precision medicine, addressing a previously untreatable genetic mutation. Amgen has secured a strong first-mover advantage in the European lung cancer treatment market with this approval.
Rapid Approval Based on Phase 2 CodeBreaK 100 Trial
This European approval was expedited based on promising data from the global Phase 2 'CodeBreaK 100' trial. The Lumykras 960mg once-daily arm demonstrated an objective response rate (ORR) of 37.1% and a median duration of response (DoR) of 11.1 months, proving tumor reduction. Regulatory authorities, recognizing the high unmet medical needs in NSCLC patients, applied the expedited CMA pathway. While a confirmatory Phase 3 trial, 'CodeBreaK 200,' remains to validate the clinical benefit, the rapid market entry is a positive step.
Revenue Growth and Intensifying Global Competition
The global KRAS inhibitor market is a high-value sector, projected to grow to over $1 billion annually. Lumykras achieved global revenue of $285 million in its first year on the US market (2022), demonstrating strong growth. However, in 2023, revenue slightly decreased to $279 million due to delayed price negotiations in various countries. Bristol Myers Squibb (BMS)'s Krazati (adagrasib), a competitor, is rapidly gaining ground, intensifying the marketing competition for market share in Europe. Amgen must now leverage its differentiated clinical data and rapidly deploy its local sales network to maintain its market share.
Health Economic Assessments and Country-Specific Price Negotiations
To achieve commercial success in the European market, Amgen must successfully negotiate pricing and reimbursement with national health authorities. Unlike the US, European countries conduct rigorous health technology assessments (HTAs), making reasonable pricing crucial for maximizing sales. Some countries, such as Germany and France, have already experienced challenges in the process of determining insurance coverage criteria and price rebates, highlighting the importance of tailored reimbursement strategies for each country. Investors should closely monitor the pace of reimbursement launches in major European countries and the quarterly trends in prescription volume.
Lumykras's European approval signifies the expansion of the KRAS G12C inhibitor market, which achieved global revenue of $285 million in 2022 and is on a growth trajectory. In the short term, it secures a first-mover advantage as the first targeted therapy for lung cancer. However, with the anticipated entry of competing drugs such as Krazati from Bristol Myers Squibb (BMS), maintaining market share will be a key indicator. In the medium to long term, it must demonstrate the reliability of the data from the confirmatory Phase 3 trial (CodeBreaK 200) to convert the conditional approval into a full approval. With multinational pharmaceutical companies accelerating the development of follow-up pipelines in the global KRAS mutation target market, which is worth approximately $1 billion, expansion of indications and clinical results of combination therapies will determine the future corporate value and market landscape.
Source: EMA (ema)